Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HIP1403 vs HGP0919 in Healthy Males
NCT02473900Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Apr 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of oseltamivir in influenza (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 48 hours, Area Under the Curve to Last Measurable Concentration at 48 hours and 1 more. Started Apr 2015; status: completed.
02
Drugs
oseltamivir
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02473900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02473900.